AMA Joins AllTrials Campaign for Clinical-trial Transparency

CHICAGO — The American Medical Assoc. (AMA) joined more than 640 patient-advocacy groups, professional societies, medical organizations, and thousands of patients worldwide in supporting the global campaign for clinical-trial registration and reporting led by AllTrials.

“The AMA strongly supports improving the timeliness and accessibility of clinical-trial data to reduce the duplication of research and help inform future research, ultimately improving health outcomes for patients,” said AMA President Dr. Steven Stack. “The AMA is pleased to join the AllTrials initiative to continue efforts aimed at ensuring open access to clinical-trial data for physicians, researchers, and patients.”

The AMA’s house of delegates recently adopted policy supporting the timely dissemination of clinical-trial data, improved enforcement deadlines for sharing these results, and expanded registration for clinical trials to improve clinical practice and policy. In alignment with this policy and upon recent approval by the AMA board of trustees, the AMA is now joining the AllTrials initiative.

“With the support of the AMA, we see the cultural change in clinical-trial transparency come significantly closer to one that will advance evidence-based medicine and improve the quality of care for all Americans,” said Lauren Quattrochi, director of AllTrials USA.

For more information on the AllTrials initiative, visit www.alltrials.net.